OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
OCULAR THERAPEUTIX, INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$6.29−0.58 (-8.44%)
Close on Oct 19, 2026
- Market cap
- $1.41B
- P/E (TTM)
- –
- Dividend yield
- –
Ocular Therapeutix statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Ocular Therapeutix | Industry median |
|---|---|---|
| Market Cap | $1.38B | $164.85M |
| Enterprise Value | $855.54M | $87.06M |
| PS Ratio | 26.54 | 3.60 |
| PB Ratio | 2.66 | 2.03 |
| P/TBV Ratio | 2.66 | 2.31 |
Enterprise value
| Measure | Ocular Therapeutix | Industry median |
|---|---|---|
| EV / Sales | 16.44 | 2.43 |
Income (trailing twelve months)
| Measure | Ocular Therapeutix | Industry median |
|---|---|---|
| Revenue | $52.05M | $57.94M |
| Gross Profit | $45.35M | $90.47M |
| Operating Income | -$313.91M | -$21.44M |
| Net Income | -$301.45M | -$22.46M |
| EBITDA | -$308.46M | -$16.91M |
| EPS (Diluted) | -$1.42 | -$0.83 |
Margins
| Measure | Ocular Therapeutix | Industry median |
|---|---|---|
| Gross Margin | 87.1% | 52.3% |
| Operating Margin | -603.0% | -44.5% |
| Profit Margin | -579.1% | -39.2% |
| EBITDA Margin | -592.6% | -31.3% |
| FCF Margin | -490.1% | -8.85% |
Returns
| Measure | Ocular Therapeutix | Industry median |
|---|---|---|
| Return on Equity (ROE) | -73.0% | -53.1% |
| Return on Assets (ROA) | -53.7% | -41.0% |
| Return on Capital Employed (ROCE) | -50.5% | -37.8% |
Growth
| Measure | Ocular Therapeutix | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -8.14% | 6.01% |
| Revenue Growth (3Y CAGR) | 0.29% | 2.25% |
| Revenue Growth (5Y CAGR) | 24.4% | 6.42% |
Balance sheet
| Measure | Ocular Therapeutix | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $598.64M | $62.42M |
| Total Debt | $72.80M | $120.13M |
| Net Cash (Debt) | $525.85M | $15.68M |
| Net Cash Per Share | $2.39 | $0.66 |
| Equity (Book Value) | $520.04M | $48.79M |
| Book Value Per Share | $2.37 | $1.36 |
| Tangible Book Value | $520.04M | $23.06M |
| Working Capital | $595.25M | $75.77M |
Financial position
| Measure | Ocular Therapeutix | Industry median |
|---|---|---|
| Current Ratio | 13.11 | 3.30 |
| Quick Ratio | 12.79 | 2.39 |
| Debt / Equity | 0.14 | 0.51 |
| Interest Coverage | -27.53 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Ocular Therapeutix | Industry median |
|---|---|---|
| Operating Cash Flow | -$238.24M | -$12.35M |
| Capital Expenditures | -$16.86M | -$1.06M |
| Free Cash Flow | -$255.10M | -$20.28M |
| FCF Per Share | -$1.16 | -$0.42 |
Efficiency
| Measure | Ocular Therapeutix | Industry median |
|---|---|---|
| Asset Turnover | 0.09 | 0.38 |
| Inventory Turnover | 1.95 | 2.67 |
| Revenue Per Employee | $160.17K | $398.96K |
| Profits Per Employee | -$927.53K | -$703.34K |
| Employee Count | 325 | 74 |
Dividends and yields
| Measure | Ocular Therapeutix | Industry median |
|---|---|---|
| Earnings Yield | -21.8% | -22.7% |
| FCF Yield | -18.5% | -9.07% |
Shares
| Measure | Ocular Therapeutix | Industry median |
|---|---|---|
| Shares Outstanding | 219,616,000 | 58,179,650 |
| Shares Change (YoY) | 26.4% | 11.1% |
| Shares Change (QoQ) | 0.32% | 0.54% |
| Float | 213,284,000 | 49,173,100 |
| Shares Held by Insiders | 2.88% | 11.6% |
| Shares Held by Institutions | 94.4% | 59.4% |
Scores
| Measure | Ocular Therapeutix | Industry median |
|---|---|---|
| Altman Z-Score | 2.32 | -0.24 |
| Piotroski F-Score | 4 | 4 |
| Beneish M-Score | -2.92 | -2.62 |
Calculated by StockData from Ocular Therapeutix's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.